CARGO Therapeutics (CRGX) Stock Price, News & Analysis

Company Overview

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Key Stats

• Today's Range: $23.69 to $24.70
• 50-Day Range: $13.84 to $25.00
• 52-Week Range: $13.14 to $33.92
• Volume: 3.74 million shs
• Average Volume: 270,748 shs
• Market Capitalization: $1.09 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.33
• Consensus Rating: Buy

CARGO Therapeutics Stock Analysis - MarketRank™

CARGO Therapeutics scored higher than 33% of companies evaluated by MarketBeat, and ranked 912th out of 1,006 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

CARGO Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

CARGO Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for CARGO Therapeutics are expected to decrease in the coming year, from ($4.37) to ($4.86) per share.

Price to Book Value per Share Ratio

CARGO Therapeutics has a P/B Ratio of 2.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.63% of the float of CARGO Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

CARGO Therapeutics has a short interest ratio ("days to cover") of 17.5, which indicates bearish sentiment.

Change versus previous month

Short interest in CARGO Therapeutics has recently increased by 13.24%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CARGO Therapeutics does not currently pay a dividend.

Dividend Growth

CARGO Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.63% of the float of CARGO Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

CARGO Therapeutics has a short interest ratio ("days to cover") of 17.5, which indicates bearish sentiment.

Change versus previous month

Short interest in CARGO Therapeutics has recently increased by 13.24%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.63

News Sentiment

CARGO Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for CARGO Therapeutics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CARGO Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.38% of the stock of CARGO Therapeutics is held by insiders.

Percentage Held by Institutions

93.16% of the stock of CARGO Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CRGX Stock Analysis - Frequently Asked Questions

How have CRGX shares performed this year?

CARGO Therapeutics' stock was trading at $23.15 on January 1st, 2024. Since then, CRGX shares have increased by 3.0% and is now trading at $23.85.
View the best growth stocks for 2024 here.

How were CARGO Therapeutics' earnings last quarter?

CARGO Therapeutics, Inc. (NASDAQ:CRGX) released its quarterly earnings data on Monday, August, 12th. The company reported ($1.02) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.04.

When did CARGO Therapeutics IPO?

CARGO Therapeutics (CRGX) raised $281 million in an initial public offering (IPO) on Friday, November 10th 2023. The company issued 18,750,000 shares at $15.00 per share.

Who are CARGO Therapeutics' major shareholders?

Top institutional investors of CARGO Therapeutics include Perceptive Advisors LLC (8.03%), Novo Holdings A S (3.37%), Yu Fan (1.99%) and Cowen AND Company LLC (1.21%). Insiders that own company stock include Samsara Biocapital Gp, Llc and Perceptive Advisors Llc.
View institutional ownership trends.

How do I buy shares of CARGO Therapeutics?

Shares of CRGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 8/12/2024
• Today: 9/20/2024
• Next Earnings (Estimated): 12/11/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRGX
• Previous Symbol: NASDAQ:CRGX
• CUSIP: N/A
• CIK: 1966494
• Web: cargo-tx.com
• Phone: 650-379-6143
• Fax: N/A
• Employees: 116
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $30.33
• High Stock Price Target: $34.00
• Low Stock Price Target: $23.00
• Potential Upside/Downside: +26.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-98,150,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -50.68%
• Return on Assets: -38.69%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.96
• Quick Ratio: 16.96

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.84 per share
• Price / Book: 2.44

Miscellaneous

• Outstanding Shares: 45,862,000
• Free Float: 45,229,000
• Market Cap: $1.10 billion
• Optionable: N/A
• Beta: N/A